Javascript must be enabled to continue!
Structural transitions in TCTP tumor protein upon Mcl-1 binding
View through CrossRef
Abstract
Summary
Translationally Controlled Tumour Protein (TCTP) is a pro-survival factor in tumor cells. TCTP inhibits the mitochondrial apoptosis pathway by potentiating the anti-apoptotic Bcl-2 family members Mcl-1 and Bcl-xL. Specifically, TCTP binds Bcl-xL and inhibits the Bax-dependent Bcl-xL-induced cytochrome c release and TCTP reduces Mcl-1 turnover by inhibiting its ubiquitinylation, thus resulting in decreased Mcl-1 mediated apoptosis. TCTP owns a BH3-like motif forming a β-strand buried in the globular domain of the protein. The crystal structure of TCTP BH3-like peptide in complex with Bcl-xL highlighted the α-helical conformation of TCTP BH3-like motif, suggesting major changes in TCTP structure upon complex formation. However, the structural impact of the interaction on the full-length TCTP and the structural description of TCTP/Mcl-1 interaction are still lacking. Here using biophysical/biochemical methods (NMR, SAXS, circular dichroism, limited proteolysis), we provide an in-depth description of the TCTP/Mcl-1 complex. We demonstrate that full length TCTP binds to the BH3 binding groove of Mcl-1 via its BH3-like motif which interconverts between different binding modes at the micro- to milli-second timescale. As a consequence of the engagement of the BH3-like motif in the interface, the TCTP globular domain is destabilized into a molten-globule state. We also establish that the residue D16 in TCTP BH3-like motif is crucial for the stability and dynamics of the intermolecular interface. As a conclusion, we reveal here in details the structural plasticity of TCTP and discuss its implications for TCTP biology and for future anticancer drug design strategies aiming at targeting TCTP complexes.
Contact
Ewen Lescop,
ewen.lescop@cnrs.fr
.
Supplementary Information
Supplementary figures, tables and files.
Title: Structural transitions in TCTP tumor protein upon Mcl-1 binding
Description:
Abstract
Summary
Translationally Controlled Tumour Protein (TCTP) is a pro-survival factor in tumor cells.
TCTP inhibits the mitochondrial apoptosis pathway by potentiating the anti-apoptotic Bcl-2 family members Mcl-1 and Bcl-xL.
Specifically, TCTP binds Bcl-xL and inhibits the Bax-dependent Bcl-xL-induced cytochrome c release and TCTP reduces Mcl-1 turnover by inhibiting its ubiquitinylation, thus resulting in decreased Mcl-1 mediated apoptosis.
TCTP owns a BH3-like motif forming a β-strand buried in the globular domain of the protein.
The crystal structure of TCTP BH3-like peptide in complex with Bcl-xL highlighted the α-helical conformation of TCTP BH3-like motif, suggesting major changes in TCTP structure upon complex formation.
However, the structural impact of the interaction on the full-length TCTP and the structural description of TCTP/Mcl-1 interaction are still lacking.
Here using biophysical/biochemical methods (NMR, SAXS, circular dichroism, limited proteolysis), we provide an in-depth description of the TCTP/Mcl-1 complex.
We demonstrate that full length TCTP binds to the BH3 binding groove of Mcl-1 via its BH3-like motif which interconverts between different binding modes at the micro- to milli-second timescale.
As a consequence of the engagement of the BH3-like motif in the interface, the TCTP globular domain is destabilized into a molten-globule state.
We also establish that the residue D16 in TCTP BH3-like motif is crucial for the stability and dynamics of the intermolecular interface.
As a conclusion, we reveal here in details the structural plasticity of TCTP and discuss its implications for TCTP biology and for future anticancer drug design strategies aiming at targeting TCTP complexes.
Contact
Ewen Lescop,
ewen.
lescop@cnrs.
fr
.
Supplementary Information
Supplementary figures, tables and files.
Related Results
Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Abstract
MCL accounts for 7% of all non-Hodgkin lymphoma cases and is a rare and incurable subtype of B-cell lymphoma. Unfortunately, most MCL patients experience di...
Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma
Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma
Introduction: Mantle cell lymphoma (MCL) is an aggressive, incurable B-cell Non-Hodgkin's lymphoma (NHL). MCL patients who progress on targeted therapies (e.g. BTK inhibitors or CA...
Flexible loop and helix 2 domains of TCTP are the functional domains of dimerized TCTP
Flexible loop and helix 2 domains of TCTP are the functional domains of dimerized TCTP
AbstractTranslationally controlled tumor protein (TCTP), also called histamine releasing factor, is an evolutionarily conserved multifunctional protein in eukaryotes. We previously...
Radiographic Predictors of Medial Collateral Ligament Injury and Stability of the Elbow
Radiographic Predictors of Medial Collateral Ligament Injury and Stability of the Elbow
Background:
It has been postulated that injury to the medial collateral ligament (MCL) of the elbow is rare in cases of elbow fracture-dislocation, and if the MCL is to...
Primary Allogeneic T-Cell Responses against Mantle Cell Lymphoma Antigen-Presenting Cells for Adoptive Immunotherapy after Stem Cell Transplantation
Primary Allogeneic T-Cell Responses against Mantle Cell Lymphoma Antigen-Presenting Cells for Adoptive Immunotherapy after Stem Cell Transplantation
Abstract
Purpose: In patients treated with allogeneic stem cell transplantation for advanced mantle cell lymphoma (MCL), complete sustained remissions have been obse...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Background: Mantle cell lymphoma (MCL), which accounts for around 7% of non-Hodgkin lymphomas, is currently incurable. MCL's key survival pathway is the B-cell receptor pathway, an...
The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Background: While mantle cell lymphoma (MCL) initially responds to frontline therapies, this aggressive B-cell malignancy typically relapses or becomes resistant to treatment. Desp...

